Home
Conditions
Recurrent Acute Myeloid Leukemia

Clinical trial condition

Recurrent Acute Myeloid Leukemia

Explore clinical trials studying Recurrent Acute Myeloid Leukemia. Study availability and eligibility vary by location and protocol.

79 public trials 32 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Acute Myeloid Leukemia trial results

Recruiting

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, +37 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05263284

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04047641

Conditions: Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, Hematologic Diseases, +18 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04493164

Conditions: Acute Myeloid Leukemia With Gene Mutations, Bone Marrow Diseases, Hematologic Diseases, +12 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

NCT06484062

Conditions: Acute Myeloid Leukemia, Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +18 more
Locations: Yale University New Haven, Connecticut, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States

UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois, United States

View all 22 locations

View Trial Details

Recruiting

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT06871410

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

NCT03629171

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

NCT02115295

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Crisis, +36 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT04774393

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +63 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recurrent Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia trial results

Related conditions